GeneDx Holdings (WGS)

• Market cap: $2.6B
• 1 day: -4.64%
• 5 days: -8.91%
• 1 month: -12.79%
• 3 months: 22.43%
• 6 months: 56.45%
• Year to date: 14.33%
• 1 year: 776.23%
• 5 years: -71.85%
• 10 years: -71.85%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Employees: 1,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

344% more first-time investments, than exits

New positions opened: 80 | Existing positions closed: 18

126% more capital invested

Capital invested by funds: $799M [Q3] → $1.81B (+$1.01B) [Q4]

109% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 33

94% more call options, than puts

Call options by funds: $18.6M | Put options by funds: $9.6M

67% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 10 (+4) [Q4]

44% more funds holding

Funds holding: 136 [Q3] → 196 (+60) [Q4]

15.59% more ownership

Funds ownership: 69.91% [Q3] → 85.51% (+15.59%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $80 12% downside
• Avg. target: $80 12% downside
• High target: $80 12% downside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Goldman Sachs Matthew Sykes 41% 1-year accuracy 14 / 34 met price target

12% downside $80

Neutral Maintained

19 Feb 2025